ArticleCancer immunology, immunotherapy : CII2025

First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study.

Giandomenico Roviello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.